中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
34期
35-36
,共2页
替比夫定%扶正化瘀胶囊%治疗应用%乙型肝炎%肝纤维化
替比伕定%扶正化瘀膠囊%治療應用%乙型肝炎%肝纖維化
체비부정%부정화어효낭%치료응용%을형간염%간섬유화
Telbivudine%Fuzhenghuayu capsule%Telbivudine therapeutic use%Hepatitis B%Liver fibrosis
目的：观察替比夫定联合扶正化瘀胶囊治疗慢性乙型病毒性肝炎纤维化的疗效。方法：将60例乙型病毒性肝炎患者（存在肝纤维化）随机分为治疗组和对照组。治疗组采用替比夫定和扶正化瘀胶囊治疗；对照组采用替比夫定治疗，疗程均为48周。观察两组治疗前后疗效、肝功、肝纤维化指标、B超指标及DNA定量变化。结果：治疗组治疗后肝功能及肝纤维化指标（HA、Ⅳ-C）均有所改善（P<0.05）；脾脏厚度明显缩小（P<0.05），门静脉和脾静脉内径较对照组缩小，但无统计学意义（P>0.05）；治疗后治疗组HBV-DNA转阴率为46%，E抗原转换率为38%，对照组分别为41%、36%，治疗组上述指标略高于对照组，但无统计学意义（P>0.05）。结论：替比夫定联合扶正化瘀胶囊治疗，能够通过抑制病毒和抗纤维化，明显改善乙型病毒性肝炎纤维化患者的病情和预后。
目的：觀察替比伕定聯閤扶正化瘀膠囊治療慢性乙型病毒性肝炎纖維化的療效。方法：將60例乙型病毒性肝炎患者（存在肝纖維化）隨機分為治療組和對照組。治療組採用替比伕定和扶正化瘀膠囊治療；對照組採用替比伕定治療，療程均為48週。觀察兩組治療前後療效、肝功、肝纖維化指標、B超指標及DNA定量變化。結果：治療組治療後肝功能及肝纖維化指標（HA、Ⅳ-C）均有所改善（P<0.05）；脾髒厚度明顯縮小（P<0.05），門靜脈和脾靜脈內徑較對照組縮小，但無統計學意義（P>0.05）；治療後治療組HBV-DNA轉陰率為46%，E抗原轉換率為38%，對照組分彆為41%、36%，治療組上述指標略高于對照組，但無統計學意義（P>0.05）。結論：替比伕定聯閤扶正化瘀膠囊治療，能夠通過抑製病毒和抗纖維化，明顯改善乙型病毒性肝炎纖維化患者的病情和預後。
목적：관찰체비부정연합부정화어효낭치료만성을형병독성간염섬유화적료효。방법：장60례을형병독성간염환자（존재간섬유화）수궤분위치료조화대조조。치료조채용체비부정화부정화어효낭치료；대조조채용체비부정치료，료정균위48주。관찰량조치료전후료효、간공、간섬유화지표、B초지표급DNA정량변화。결과：치료조치료후간공능급간섬유화지표（HA、Ⅳ-C）균유소개선（P<0.05）；비장후도명현축소（P<0.05），문정맥화비정맥내경교대조조축소，단무통계학의의（P>0.05）；치료후치료조HBV-DNA전음솔위46%，E항원전환솔위38%，대조조분별위41%、36%，치료조상술지표략고우대조조，단무통계학의의（P>0.05）。결론：체비부정연합부정화어효낭치료，능구통과억제병독화항섬유화，명현개선을형병독성간염섬유화환자적병정화예후。
Objective:To observe the effect of telbivudine combined with Fuzhenghuayu capsule on the treatment of chronic hepatitis B and liver fibrosis. Method:60 cases of patients with hepatitis B virus(accompanied with fibrosis)were randomly divided into treatment group and control group. The treatment group were treated with telbivudine and Fuzhenghuayu capsule,the control group were treated with telbivudine therapy. The course of the treatment continued for 48 weeks. The symptoms,signs,liver function,hepatic fibrosis index,DNA index and quantitative change of B ultrasound of patients in two groups were observed and compared before and after treatment. Result:Treatment group after treatment of liver function and liver fibrosis index(HA,Ⅳ-C)were improved(P<0.05);Thickness of spleen significant reduction(P<0.05),portal vein and splenic vein diameter was smaller, but without statistical significance(P>0.05);Treatment group after treatment of HBV-DNA overcast rate was 46%,E antigen conversion rate was 38%,the control group were 41%,36%,the index of the treatment group slightly higher than the control group,but no statistical significance(P>0.05). Conclusion:Telbivudine combined with Fuzhenghuayu capsule can suppress the virus and anti fibrosis,significantly improve condition and prognosis of patients with hepatitis B fibrosis.
